Published August 6, 2021
| Version v1
Dataset
Open
Data set: Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomide (TMZ).
Authors/Creators
- 1. Department of Biological Sciences,Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA Hunter College of The City University of New York, New York, NY, USA ,
- 2. Steinbrenner Laborsysteme GmbH, Wiesenbach, Germany
- 3. Department of Biological Sciences, Hunter College for Cancer Health Disparities Research, Hunter College of The City University of New York, New YorkJoan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA, Hunter College of The City University of New York, New York, NY, USA ,
Description
Glioblastoma is the deadliest of all primary brain tumor with a very poor survival outcome. Alkylating agent such as temozolomide is used as a mainstay drug used in treating of glioblastoma patients including radiation, tumor treating field and surgery. However, this drug offers little to no benefit for the glioblastoma patients. Hence, the objective of the generation of this data is to understand and unravel genes that controls glioblastoma susceptibility and resistance to temozolomide using an unbiased genome scale CRISPR Cas9a knockout screen
Files
5953_DMSO_Day14_R2.txt
Files
(14.6 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:7417ffb0b7e742bdb16ebcbd8cb5116e
|
2.4 MB | Preview Download |
|
md5:b4cff0cee65a6b2e07d303cb57a2c479
|
2.5 MB | Preview Download |
|
md5:0d7d5c5b12af4d79443c743df12c8591
|
2.4 MB | Preview Download |
|
md5:63fe3ae935d8b0e699305b0a7d3dc74f
|
2.4 MB | Preview Download |
|
md5:b09c1d0a21c44e178728212d23f71e7f
|
2.4 MB | Preview Download |
|
md5:d5a7d53a72658acc93f0695745e6f7a8
|
2.4 MB | Preview Download |